Merck Raises 2026 Profit Outlook to $2.77-$2.82 a Share as Keytruda Sales Hit $8.6B
The Facts
- Merck reported Q3 2026 revenue of $18.09 billion, up 5% from a year earlier. CNBC only
- Merck posted Q3 net income of $5.07 billion ($2.04 per share), compared with $5.79 billion ($2.32 per share) a year earlier. CNBC only
- Excluding acquisition and restructuring costs, Merck earned $2.49 per share in Q3. CNBC only
- Merck raised its 2026 adjusted EPS guidance to $2.77-$2.82 from $2.66-$2.76, including a one-time $400 million (12 cents per share) charge tied to a licensing agreement with Chinese drugmaker SciBrunch. CNBC only
- Merck narrowed the low end of its 2026 revenue guidance to $66.8 billion-$67.3 billion, from $66.3 billion-$67.3 billion. CNBC only
Dive deeper · 6 more factsShow less
- Keytruda sales were $8.60 billion in Q3, versus $7.73 billion expected by analysts per StreetAccount. CNBC only
- Sales of the injectable Keytruda Qlex, launched in 2025, were $830 million, its highest quarter yet, versus $649 million expected per StreetAccount. CNBC only
- Winrevair sales were $694 million, up 93% year over year, versus $645 million expected. CNBC only
- Gardasil sales were about $2 billion, versus $1.76 billion expected, on higher U.S. demand. CNBC only
- Merck's animal health sales were $1.68 billion, slightly below analyst estimates. CNBC only
- Key Keytruda patents begin expiring in 2028; Merck is pushing patients from the intravenous version to Qlex, a subcutaneous injection. CNBC only
Context
Merck reported third-quarter results on Thursday that beat analyst estimates and raised its full-year adjusted profit forecast, driven by Keytruda and its newer under-the-skin form, Keytruda Qlex.
The company is working to offset expected generic competition for Keytruda after key patents begin expiring in 2028, including through licensing deals and the shift to Qlex.
How the Agent Panel Scored This
Independent AI personas each scored importance 1–10; the story's score is a trimmed mean (highest and lowest votes dropped). Vote spread: 4.
| 7 | Business Analyst | Merck, a major pharma company, beat earnings across key products and raised its 2026 profit guidance, a concrete corporate result with meaningful market impact on a bellwether drugmaker, though it is a single company's quarterly earnings rather than broad market-moving news. |
| 5 | News Editor | A large pharmaceutical company's earnings beat and raised guidance is a concrete, market-moving corporate event affecting investors and the drug industry, but it is a routine quarterly report with limited broad public impact, so it sits in the moderate range. |
| 5 | Science & Tech Analyst | A major pharma's quarterly earnings beat and guidance raise is newsworthy for investors and the Keytruda patent-cliff strategy, but it is a corporate financial report with limited broader public impact. |
| 5 | Critical Reader | A large pharma's quarterly earnings beat and guidance raise is a concrete, verified financial event with moderate market impact, but it affects mainly investors and is a routine periodic report rather than major breaking news. |
| 4 | Informed Citizen | This is a corporate earnings report for a single drugmaker, beating estimates and raising guidance, which matters mainly to investors and has limited direct impact on ordinary people within a week. |
| 4 | Policy Expert | This is a corporate earnings report and guidance raise from a single source, a company-level financial event affecting investors more than the broad public, so it is minor-to-moderate news with limited wide impact. |
| 3 | Global Affairs Analyst | This is a corporate quarterly earnings report with beats and a guidance raise for one pharmaceutical company, which is business news of limited geopolitical significance, though the SciBrunch China licensing charge gives it a slight cross-border angle. |